In a meta-analysis, Li et al. also identified tumor PD-L1 expression and mutational burden as predictive biomarkers (both with specificity of about 30% when sensitivity is 80%) for anti-PD-(L)1 treatment in NSCLC49,50. The gene discussed is CD274; the disease is neoplasm.